ARWR shares +17% premarket after said phase 3 SHASTA-3 and SHASTA-4 studies of Plozasiran in severe Hypertriglyceridemia met primary endpoin

ARWR shares +17% premarket after said phase 3 SHASTA-3 and SHASTA-4 studies of Plozasiran in severe Hypertriglyceridemia met primary endpoints. In SHASTA-3 and SHASTA-4, 25 mg Plozasiran administered as a subcutaneous injection once every three months led to median triglyceride reductions of 79% and 81%, respectively, at month 12, versus a placebo reduction of ~27%.